BioSpace News Archive

Spherix Incorporated (Nasdaq: SPEX) today announced results from the Special Meeting of Shareholders held on September 5th (the “Meeting”).

Eli Lilly and Company presented data from the LIBRETTO-001 clinical trial intended to support the registration of oral selpercatinib[1] monotherapy, also known as LOXO-292, for the treatment of RET fusion-positive non-small cell lung cancer.

Aptorum Group Limited announces that it has initiated investigational new drug (IND)-enabling studies for ALS-4, a small drug molecule candidate indicated for the treatment of infections caused by Staphylococcus aureus (or “S. aureus”) including methicillin-resistant Staphylococcus aureus (MRSA, i.e., one of the commonly known “super-bugs”) based on a novel anti-virulence approach.

Vizient, Inc., has recognized 269 member health care organizations for demonstrating excellence in lowering costs in the supply chain.

Aptorum Group Limited provided a business update and announced financial results for the six months ended June 30, 2019.

Facility Expansion Remains on Schedule to Increase Capacity and Further Improve Efficiencies of Scale

ACADIA Pharmaceuticals Inc. announced that its Phase 3 HARMONY study, a double-blind, placebo-controlled relapse prevention trial evaluating pimavanserin for the treatment of dementia-related psychosis, met its primary endpoint, demonstrating a highly statistically significant longer time to relapse of psychosis with pimavanserin compared to placebo in a planned interim efficacy analysis.

Steven Altschuler, M.D., Managing Director of Ziff Capital Partners and Chairman of Spark Therapeutics, joins PBG’s Board of Directors

Includes $3.5M from group of U.S. accredited investors with deep expertise in 3D printing

CytoSorbents Corporation announced that its Chief Executive Officer, Dr. Phillip Chan, MD, PhD, will present an overview of the company at the 21st Annual Global Investment Conference sponsored by H.C. Wainwright & Co. on Tuesday, September 10, 2019 in New York, NY. Both Dr. Chan and Chief Financial Officer, Kathleen Bloch will meet with investors in 1x1 meetings during the conference on September 9-10, 2019.